Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) has been assigned a consensus rating of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $10.78.
A number of research firms have commented on ZNTL. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Oppenheimer restated an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Jefferies Financial Group restated a “hold” rating and set a $6.00 price objective (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research report on Monday, August 12th. Finally, Morgan Stanley restated an “equal weight” rating and set a $8.00 price objective (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th.
Read Our Latest Stock Report on Zentalis Pharmaceuticals
Institutional Investors Weigh In On Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Stock Up 1.7 %
NASDAQ:ZNTL opened at $2.99 on Thursday. The business’s 50-day simple moving average is $3.36 and its two-hundred day simple moving average is $7.23. The stock has a market cap of $212.62 million, a PE ratio of -1.10 and a beta of 1.70. Zentalis Pharmaceuticals has a 52 week low of $2.83 and a 52 week high of $19.14.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter last year, the company earned ($1.85) earnings per share. Sell-side analysts anticipate that Zentalis Pharmaceuticals will post -3.02 earnings per share for the current fiscal year.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
See Also
- Five stocks we like better than Zentalis Pharmaceuticals
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What Do S&P 500 Stocks Tell Investors About the Market?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Insider Buying Explained: What Investors Need to Know
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.